663 Results for "

Cell Invasion

" in MedChemExpress (MCE) Product Catalog:
Products (663)

663 Results for "Cell Invasion" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-13495
CAS No.: 1404437-62-2
Purity:  99.91%
ML281 is a highly selective inhibitor of serine/threonine kinase 33 (STK33) with an IC50 value of 14 nM. ML281 shows 700-fold selectivity over PKA and 550-fold over AurB. ML281 exerts core mechanism by inhibiting STK33: in small cell lung cancer, ML281 downregulates RPS6/BAD signaling phosphorylation, induces apoptosis, and suppresses proliferation, invasion . ML281 reduces STK33-mediated 4-hydroxyphenylpyruvate dioxygenase (HPD) phosphorylation in tyrosinemia . ML281 is suitable for research on STK33 function, KRAS mutation-related cancers (pancreatic cancer, colon cancer, lung adenocarcinoma, etc.), small cell lung cancer, and tyrosinemia-related damage
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0580B
CAS No.: 66635-93-6
Synonyms: (+)-Ketorolac
Target:  

Ras

Research Areas:  

Cancer

(R)-Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R)-Ketorolac inhibits GTPase. (R)-Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R)-Ketorolac ameliorates cancer-associated cachexia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P2230
CAS No.: 220334-14-5
Synonyms: A6 Peptide
Target:  

PAI-1

Research Areas:  

Cancer

Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18619
CAS No.: 36341-25-0
Research Areas:  

Cancer

YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-75954
CAS No.: 6064-63-7
2-Hydroxyhexanoic acid is a metabolite. 2-Hydroxyhexanoic acid is elevated in metastatic pancreatic neuroendocrine tumors. 2-Hydroxyhexanoic acid does not promote the proliferation, migration or invasion of pancreatic neuroendocrine tumor cells. 2-Hydroxyhexanoic acid can be used in the research of metastatic pancreatic neuroendocrine tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1260
CAS No.: 57-09-0
Synonyms: CTAB; Cetyltrimethylammonium bromide; Hexadecyltrimethylammonium bromide
Cetrimonium bromide (CTAB), a quaternary ammonium, is an orally active cationic surfaetant. Cetrimonium bromide has toxicity and anticancer effect. Cetrimonium bromide inhibits cell migration and invasion through modulating the canonical and non-canonical TGF-β signaling pathways. Cetrimonium bromide can be used for DNA extraction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109523
CAS No.: 143201-11-0
Purity:  99.84%
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16511
CAS No.: 590368-25-5
Synonyms: WX-671
Target:  

PAI-1 Ser/Thr Protease

Research Areas:  

Infection Cancer

Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-115568
CAS No.: 2140289-17-2
Purity:  98.34%
Research Areas:  

Cancer

BETd-246 is a BRD2/3/4 PROTAC degrader targeting the BET family. BETd-246 induces ubiquitination and proteasomal degradation of BRD2, BRD3 and BRD4 by recruiting the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex; it also inhibits TRAT1 expression and depletes BET proteins. BETd-246 suppresses cancer cell proliferation and invasion, disrupts the cell cycle and induces apoptosis. BETd-246 is applicable to research related to triple-negative breast cancer and T-cell acute lymphoblastic leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16782
CAS No.: 945614-12-0
Synonyms: ARRY-614
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99463
CAS No.: 2268717-61-7
Synonyms: AVB-500; AVB-S6-500

Research Areas:  

Cancer

Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-134601
CAS No.: 1215115-03-9
Purity:  98.91%
Target:  

HuR

Research Areas:  

Cancer

KH-3 is a potent RNA-binding protein Hu antigen R (HuR) inhibitor with an IC50 value of 0.35 μM. KH-3 has anti-proliferative activity. KH-3 suppresses breast cancer cell invasion as well as delays the initiation of lung colonies by disrupting HuR-FOXQ1 mRNA interaction .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136383
CAS No.: 1071098-42-4
Purity:  98.07%
Synonyms: Rac1/Cdc42-IN-1
Target:  

Ras Apoptosis

Research Areas:  

Cancer

AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112476
CAS No.: 893449-38-2
Purity:  99.10%
Target:  

Phosphatase

Research Areas:  

Cancer

PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC50 of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16916
CAS No.: 448895-37-2
Research Areas:  

Cancer

NS1643 is a partial agonist of human ether-a-go-go-related gene (hERG) K + channels with an EC50 of 10.5 μM. NS1643 inhibits the growth of breast cancer tumors in TNBC mouse models. NS1643 inhibits cell migration and invasion of breast cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120231
CAS No.: 1381885-28-4
Target:  

MALT1 NF-κB MMP

Research Areas:  

Cancer

Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N4107
CAS No.: 10351-88-9
Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162143
CAS No.: 727686-80-8
Target:  

SphK Akt mTOR

Research Areas:  

Cancer

SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-NP132A
Recombinant humanized type III collagen (MW 55900) is a type III collagen with a molecular weight of 55900 Da. Recombinant humanized type III collagen has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. Recombinant humanized type III collagen inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W011338
CAS No.: 85-68-7
Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs) .
loading...
    loading...